How many days before a robotic cholecystectomy should a patient stop taking aspirin 81 mg daily?

Aspirin Management for Robotic Cholecystectomy

For patients taking aspirin 81 mg daily undergoing robotic cholecystectomy, continue aspirin through the perioperative period without interruption.

Primary Recommendation

The evidence strongly supports continuation of low-dose aspirin for laparoscopic/robotic cholecystectomy rather than holding it preoperatively. This is based on:

• Direct surgical evidence: A study of over 800 laparoscopic cholecystectomies found that continuation of aspirin monotherapy was safe, with no increased intraoperative bleeding complications 1. The study specifically showed that preoperative continuation of aspirin or multiple antiplatelet therapy use did not affect intraoperative bleeding complications.

• Additional cholecystectomy data: Research comparing 270 laparoscopic cholecystectomy patients found no significant difference in blood loss, transfusion rates, or postoperative morbidity between aspirin-treated and non-aspirin-treated patients 2. The only difference was slightly longer surgical duration in aspirin patients, which had no clinical consequence.

• Gastrointestinal surgery evidence: A 2024 study of 1,001 gastrectomy patients (a higher-risk procedure than cholecystectomy) demonstrated that continuing aspirin monotherapy preoperatively had no impact on intraoperative or postoperative bleeding 3.

Risk-Benefit Analysis

Thrombotic risk of stopping aspirin outweighs bleeding risk of continuing it:

• Cholecystectomy is not classified as a high-bleeding-risk procedure where aspirin discontinuation would be essential (unlike neurosurgery or spinal surgery) 4
• The robotic/laparoscopic approach further reduces bleeding risk compared to open surgery
• Aspirin discontinuation creates a rebound hypercoagulable state that increases cardiovascular and thrombotic events 5

If Discontinuation Were Considered (Not Recommended)

Should you encounter a situation requiring aspirin interruption (e.g., patient-specific extreme bleeding risk), the evidence indicates:

• 3-5 days is sufficient for most procedures 6, 7, 8
• Platelet function normalizes within 96-144 hours (4-6 days) after aspirin cessation 8, 4
• Traditional 7-10 day holds are unnecessarily long and increase thrombotic risk 7

However, this approach is NOT recommended for routine cholecystectomy.

Clinical Pitfalls to Avoid

1. Don't confuse aspirin with P2Y12 inhibitors: Clopidogrel, prasugrel, and ticagrelor require 5-7 days discontinuation for high-bleeding-risk surgeries 9, but cholecystectomy doesn't fall into this category

2. Don't use "bridging" anticoagulation: Low molecular weight heparins should not replace aspirin perioperatively—they increase bleeding without providing equivalent antiplatelet protection 4

3. Recognize aspirin resistance exists: Up to 43-56% of patients on aspirin may have normal platelet function despite taking the medication 10, meaning discontinuation may be unnecessary even from a theoretical standpoint

Postoperative Management

• Resume aspirin immediately postoperatively if it was held (ideally same day once hemostasis confirmed) 4
• Continue aspirin 81 mg daily indefinitely for the underlying cardiovascular indication 11

The evidence consistently demonstrates that robotic/laparoscopic cholecystectomy can be performed safely in patients continuing aspirin 81 mg daily, with no clinically significant increase in bleeding complications.